Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC‐H 106
Abstract The importance of vesicular monoamine transporter 2 (VMAT2) in dopamine regulation, which is considered crucial for neuropsychiatric disorders, is currently being studied. Moreover, the development of disease treatments using histone deacetylase (HDAC) inhibitors (HDACi) is actively progres...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-10-01
|
| Series: | Pharmacology Research & Perspectives |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/prp2.1135 |
| _version_ | 1797658922336649216 |
|---|---|
| author | Heejin Lee Hye‐Ji Kim Dong‐Kyu Choi Eu n.‐A. Ko Jae‐Hyeog Choi Yohan Seo Sion Lee Soong‐Hyun Kim Sejin Jung Minwoo Kim Dongwan Kang Chun‐Young Im Gi‐Hun Bae Sung‐Cherl Jung Oh‐Bin Kwon |
| author_facet | Heejin Lee Hye‐Ji Kim Dong‐Kyu Choi Eu n.‐A. Ko Jae‐Hyeog Choi Yohan Seo Sion Lee Soong‐Hyun Kim Sejin Jung Minwoo Kim Dongwan Kang Chun‐Young Im Gi‐Hun Bae Sung‐Cherl Jung Oh‐Bin Kwon |
| author_sort | Heejin Lee |
| collection | DOAJ |
| description | Abstract The importance of vesicular monoamine transporter 2 (VMAT2) in dopamine regulation, which is considered crucial for neuropsychiatric disorders, is currently being studied. Moreover, the development of disease treatments using histone deacetylase (HDAC) inhibitors (HDACi) is actively progressing in various fields. Recently, research on the possibility of regulating neuropsychiatric disorders has been conducted. In this study, we evaluated whether VMAT2 expression increased by an HDACi can fine‐tune neuropsychotic behavior, such as attention deficit hyperactivity disorder (ADHD) and protect against the cell toxicity through oxidized dopamine. First, approximately 300 candidate HDACi compounds were added to the SH‐SY5Y dopaminergic cell line to identify the possible changes in the VMAT2 expression levels, which were measured using quantitative polymerase chain reaction. The results demonstrated, that treatment with pimelic diphenylamide 106 (TC‐H 106), a class I HDACi, increased VMAT2 expression in both the SH‐SY5Y cells and mouse brain. The increased VMAT2 expression induced by TC‐H 106 alleviated the cytotoxicity attributed to 6‐hydroxydopamine (6‐OHDA) or 1‐methyl‐4‐phenylpyridinium (MPP+) and free dopamine treatment. Moreover, dopamine concentrations, both intracellularly and in the synaptosomes, were significantly elevated by increased VMAT2 expression. These results suggest that dopamine concentration regulation by VMAT2 expression induced by TC‐H 106 could alter several related behavioral aspects that was confirmed by attenuation of hyperactivity and impulsivity, which were major characteristics of animal model showing ADHD‐like behaviors. These results indicate that HDACi‐increased VMAT2 expression offers sufficient protections against dopaminergic cell death induced by oxidative stress. Thus, the epigenetic approach could be considered as therapeutic candidate for neuropsychiatric disease regulation. |
| first_indexed | 2024-03-11T18:06:25Z |
| format | Article |
| id | doaj.art-a831498fedc040b8a74e3e58dc2baca1 |
| institution | Directory Open Access Journal |
| issn | 2052-1707 |
| language | English |
| last_indexed | 2024-03-11T18:06:25Z |
| publishDate | 2023-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pharmacology Research & Perspectives |
| spelling | doaj.art-a831498fedc040b8a74e3e58dc2baca12023-10-17T07:30:29ZengWileyPharmacology Research & Perspectives2052-17072023-10-01115n/an/a10.1002/prp2.1135Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC‐H 106Heejin Lee0Hye‐Ji Kim1Dong‐Kyu Choi2Eu n.‐A. Ko3Jae‐Hyeog Choi4Yohan Seo5Sion Lee6Soong‐Hyun Kim7Sejin Jung8Minwoo Kim9Dongwan Kang10Chun‐Young Im11Gi‐Hun Bae12Sung‐Cherl Jung13Oh‐Bin Kwon14New Drug Development Center, K‐Medihub Daegu KoreaDepartment of Physiology, School of Medicine Jeju National University Jeju KoreaNew Drug Development Center, K‐Medihub Daegu KoreaDepartment of Physiology, School of Medicine Jeju National University Jeju KoreaNew Drug Development Center, K‐Medihub Daegu KoreaNew Drug Development Center, K‐Medihub Daegu KoreaNew Drug Development Center, K‐Medihub Daegu KoreaNew Drug Development Center, K‐Medihub Daegu KoreaNew Drug Development Center, K‐Medihub Daegu KoreaNew Drug Development Center, K‐Medihub Daegu KoreaNew Drug Development Center, K‐Medihub Daegu KoreaNew Drug Development Center, K‐Medihub Daegu KoreaNew Drug Development Center, K‐Medihub Daegu KoreaDepartment of Physiology, School of Medicine Jeju National University Jeju KoreaNew Drug Development Center, K‐Medihub Daegu KoreaAbstract The importance of vesicular monoamine transporter 2 (VMAT2) in dopamine regulation, which is considered crucial for neuropsychiatric disorders, is currently being studied. Moreover, the development of disease treatments using histone deacetylase (HDAC) inhibitors (HDACi) is actively progressing in various fields. Recently, research on the possibility of regulating neuropsychiatric disorders has been conducted. In this study, we evaluated whether VMAT2 expression increased by an HDACi can fine‐tune neuropsychotic behavior, such as attention deficit hyperactivity disorder (ADHD) and protect against the cell toxicity through oxidized dopamine. First, approximately 300 candidate HDACi compounds were added to the SH‐SY5Y dopaminergic cell line to identify the possible changes in the VMAT2 expression levels, which were measured using quantitative polymerase chain reaction. The results demonstrated, that treatment with pimelic diphenylamide 106 (TC‐H 106), a class I HDACi, increased VMAT2 expression in both the SH‐SY5Y cells and mouse brain. The increased VMAT2 expression induced by TC‐H 106 alleviated the cytotoxicity attributed to 6‐hydroxydopamine (6‐OHDA) or 1‐methyl‐4‐phenylpyridinium (MPP+) and free dopamine treatment. Moreover, dopamine concentrations, both intracellularly and in the synaptosomes, were significantly elevated by increased VMAT2 expression. These results suggest that dopamine concentration regulation by VMAT2 expression induced by TC‐H 106 could alter several related behavioral aspects that was confirmed by attenuation of hyperactivity and impulsivity, which were major characteristics of animal model showing ADHD‐like behaviors. These results indicate that HDACi‐increased VMAT2 expression offers sufficient protections against dopaminergic cell death induced by oxidative stress. Thus, the epigenetic approach could be considered as therapeutic candidate for neuropsychiatric disease regulation.https://doi.org/10.1002/prp2.1135ADHDdopamineHDACIVMAT2 |
| spellingShingle | Heejin Lee Hye‐Ji Kim Dong‐Kyu Choi Eu n.‐A. Ko Jae‐Hyeog Choi Yohan Seo Sion Lee Soong‐Hyun Kim Sejin Jung Minwoo Kim Dongwan Kang Chun‐Young Im Gi‐Hun Bae Sung‐Cherl Jung Oh‐Bin Kwon Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC‐H 106 Pharmacology Research & Perspectives ADHD dopamine HDACI VMAT2 |
| title | Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC‐H 106 |
| title_full | Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC‐H 106 |
| title_fullStr | Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC‐H 106 |
| title_full_unstemmed | Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC‐H 106 |
| title_short | Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC‐H 106 |
| title_sort | dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by vmat2 expression through the class i hdac inhibitor tc h 106 |
| topic | ADHD dopamine HDACI VMAT2 |
| url | https://doi.org/10.1002/prp2.1135 |
| work_keys_str_mv | AT heejinlee dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT hyejikim dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT dongkyuchoi dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT eunako dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT jaehyeogchoi dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT yohanseo dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT sionlee dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT soonghyunkim dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT sejinjung dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT minwookim dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT dongwankang dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT chunyoungim dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT gihunbae dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT sungcherljung dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 AT ohbinkwon dopaminergiccellprotectionandalleviationofneuropsychiatricdiseasesymptomsbyvmat2expressionthroughtheclassihdacinhibitortch106 |